Carboplatin
- Generic Name
- Carboplatin
- Brand Names
- Paraplatin
- Drug Type
- Small Molecule
- Chemical Formula
- C6H12N2O4Pt
- CAS Number
- 41575-94-4
- Unique Ingredient Identifier
- BG3F62OND5
- Background
Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.
Carboplatin was granted FDA approval on 3 March 1989.
- Indication
Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.
- Associated Conditions
- Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma
- Associated Therapies
- Conditioning regimens for allogeneic stem cell transplantation therapy
AK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-06-15
- Last Posted Date
- 2024-03-06
- Lead Sponsor
- Akeso
- Target Recruit Count
- 233
- Registration Number
- NCT05904379
- Locations
- 🇨🇳
Shanghai Pulmonary Hospital, Shanghai, China
🇨🇳Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Trilaciclib Prior to Chemotherapy Plus Tislelizumab as 1L Treatment for Advanced Squamous Non-Small-Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-06-13
- Last Posted Date
- 2023-06-13
- Lead Sponsor
- Sichuan University
- Target Recruit Count
- 132
- Registration Number
- NCT05900921
Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM
- Conditions
- Interventions
- First Posted Date
- 2023-06-13
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- CarThera
- Target Recruit Count
- 560
- Registration Number
- NCT05902169
- Locations
- 🇫🇷
Hôpital Neurologique Pierre Wertheimer, Bron, France
🇫🇷Hôpital de La Timone, Marseille, France
🇫🇷Hôpital de la Pitié-Salpêtrière, Paris, France
TCb vs EC-T in High Risk ER+/HER2- Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-06-13
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 1736
- Registration Number
- NCT05901428
- Locations
- 🇨🇳
Breast cancer institute of Fudan University Cancer Hospital, Shanghai, Shanghai, China
Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer
- First Posted Date
- 2023-06-12
- Last Posted Date
- 2024-03-08
- Lead Sponsor
- Karolinska University Hospital
- Target Recruit Count
- 370
- Registration Number
- NCT05900206
- Locations
- 🇸🇪
Stockholm Southern Hospital, Stockholm, Sweden
🇸🇪Skåne University Hospital, Malmö, Sweden
🇸🇪Sankt Gorans Hospital, Stockholm, Sweden
Neoadjuvant Therapy With Toripalimab and JS004 Combined With Platinum-based Doublet Chemotherapy for Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer: A Randomised Controlled, Open-label, Phase 2 Trial
- Conditions
- Interventions
- First Posted Date
- 2023-06-06
- Last Posted Date
- 2023-06-06
- Lead Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
- Target Recruit Count
- 124
- Registration Number
- NCT05891080
Neoadjuvant Concomitant Modulated Electro-hyperthermia in HER2-negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-06-05
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Semmelweis University
- Target Recruit Count
- 71
- Registration Number
- NCT05889390
- Locations
- 🇭🇺
Division of Oncology, Department of Internal Medicine and Oncology, Semmelweis University, Budapest, Hungary
EC-THP Versus TCbHP in HER2-positive Lymph Node Positive Early Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-06-01
- Last Posted Date
- 2023-06-27
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 1406
- Registration Number
- NCT05883852
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center Shanghai, China, 200032, Shanghai, Shanghai, China
Effect of Platinum-based Versus Non-platinum-based Neoadjuvant Chemotherapy in Triple-negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-05-24
- Last Posted Date
- 2023-05-25
- Target Recruit Count
- 82
- Registration Number
- NCT05872412
- Locations
- 🇧🇩
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
A Phase III Study of SKB264 for EGFR Mutant NSCLC Patients
- Conditions
- Interventions
- First Posted Date
- 2023-05-23
- Last Posted Date
- 2023-08-08
- Target Recruit Count
- 356
- Registration Number
- NCT05870319
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.